The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.

Autor:	Özdemir Ö; Departments of Medical Oncology., Zengel B; General Surgery, Bozyaka Training and Research Hospital., Yildiz Y; Department Medical of Oncology, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir., Uluç BO; Department of Medical Oncology, Acibadem Hospital, Istanbul., Cabuk D; Department of Medical Oncology, Kocaeli University Faculty of Medicine Hospital, Kocaeli., Ozden E; Department of Medical Oncology, Kocaeli University Faculty of Medicine Hospital, Kocaeli., Salim DK; Department of Medical Oncology, Health Sciences University Antalya Training and Research Hospital, Antalya., Paydas S; Department of Medical Oncology, Cukurova University Faculty of Medicine, Adana, Turkey., Demir A; Department of Medical Oncology, Acibadem Hospital, Istanbul., Diker O; Department of Medical Oncology, Near East University Hospital, Lefkosa, Cyprus., Pilanci KN; Department of Medical Oncology, Memorial Bahcelievler Hospital., Sönmez ÖU; Department of Medical Oncology, Acibadem Hospital, Istanbul., Vatansever S; Department of Medical Oncology, Istanbul University Faculty of Medicine, Istanbul., Dogan I; Department of Medical Oncology, Istanbul University Faculty of Medicine, Istanbul., Gulmez A; Department of Medical Oncology, Inonu University Faculty of Medicine, Malatya., Cakar B; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir., Gursoy P; Department of Medical Oncology, Ege University Faculty of Medicine, Izmir., Yildirim ME; Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul., Ayhan M; Department of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul., Karadurmus N; Department of Medical Oncology, Health Sciences University Gulhane Training and Research Hospital, Ankara., Aykan MB; Department of Medical Oncology, Health Sciences University Gulhane Training and Research Hospital, Ankara., Cevik GT; Department of Medical Oncology, Usak University Training and Research Hospital, Usak., Sakalar T; Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras., Hacibekiroglu I; Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya., Gülbagci BB; Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya., Dincer M; Department of Medical Oncology, Osmangazi University Faculty of Medicine Hospital, Eskisehir., Garbioglu DB; Department of Medical Oncology, Osmangazi University Faculty of Medicine Hospital, Eskisehir., Kemal Y; Department of Medical Oncology, Medical Park Hospital, Samsun., Nayir E; Department of Medical Oncology, Medical Park Hospital, Mersin., Taskaynatan H; Department of Medical Oncology, Private Ege City Hospital, Izmir., Yilmaz M; Department of Medical Oncology, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul., Avci O; Department of Medical Oncology, Namik Kemal University Hospital, Tekirdag., Sari M; Department of Medical Oncology, Haydarpaşa Numune Training and Research Hospital., Coban E; Department of Medical Oncology, Haydarpaşa Numune Training and Research Hospital., Atci MM; Department of Medical Oncology, Prof. Dr. Cemil Tascioğlu City Hospital, Istanbul., Esen SA; Department of Medical Oncology, Ankara City Hospital, Ankara., Telli TA; Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul., Karatas F; Department of Medical Oncology, Karabuk University Faculty of Medicine, Karabuk., Inal A; Department of Medical Oncology, Mersin City Training and Research Hospital, Mersin., Demir H; Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar., Kalkan NO; Department of Medical Oncology, Van Yuzuncu Yil Faculty of Medicine, Van., Yilmaz C; Departments of Medical Oncology., Tasli F; Department of Pathology, Bozyaka Training and Research Hospital, Izmir, Turkey., Alacacioglu A; Department Medical of Oncology, Katip Çelebi University, Atatürk Training and Research Hospital, Izmir.
Jazyk:	angličtina
Zdroj:	Anti-cancer drugs [Anticancer Drugs] 2022 Aug 01; Vol. 33 (7), pp. 663-670. Date of Electronic Publication: 2022 Jun 20.
DOI:	10.1097/CAD.0000000000001310
Abstrakt:	In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted by the Turkish Oncology Group (TOG) with data collected from 32 centers. Our study was multicentric, and a total of 364 patients were included. The median age of the patients was 49 years (18-85 years). Two hundred fifteen (60%) of the cases were hormone receptor/HER2+ positive(ER+ or PR+, or both), and 149 (40%) of them were HER2-rich (ER and PR negative). The number of complete responses was 124 (54%) in the docetaxel+trastuzumab+pertuzumab arm and 102 (45%) in the paclitaxel+trastuzumab+pertuzumab arm, and there was no difference between the groups in terms of complete response. In 226 (62%) patients with complete response, a significant correlation was found with DCIS, tumor focality, removed lymph node, and ER status P < 0.05. Anemia, nausea, vomiting, myalgia, alopecia, and mucosal inflammation were significantly higher in the docetaxel arm, P < 0.05. In our study, no statistical difference was found between the before-after echocardiography values. DCIS positivity in biopsy before neoadjuvant chemotherapy, tumor focality; the number of lymph nodes removed and ER status were found to be associated with pCR. In conclusion, we think that studies evaluating pCR-related clinicopathological variables and radiological imaging features will play a critical role in the development of nonsurgical treatment approaches. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu